BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
4/23/2026 11:05:46 AM | Browse: 102 | Download: 413
Publication Name World Journal of Methodology
Manuscript ID 114269
Country Morocco
ISSN 2222-0682 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Immunology
Manuscript Type Minireviews
Article Title Interleukin-1 receptor antagonist autoantibodies in Still’s disease: Mechanistic insights and laboratory testing
Manuscript Source Invited Manuscript
All Author List Abdellatif Bouayad
ORCID
Author(s) ORCID Number
Abdellatif Bouayad http://orcid.org/0000-0003-4377-0833
Funding Agency and Grant Number
Corresponding Author Abdellatif Bouayad, Associate Professor, MD, Department of Immunology, Mohammed First University, Faculty of Medicine and Pharmacy Oujda, 4867 Oujda l’Université, Oujda-Angad 4867, Oriental, Morocco. a.bouayad@ump.ac.ma
Key Words Still’s disease; Interleukin-1 receptor antagonist autoantibodies; Pathogenesis; Enzyme-linked immunosorbent; Isoelectric focusing; Western blot; Interleukin-1β signaling reporter cell assays
Core Tip Still’s disease is a rare, severe systemic inflammatory disorder characterized by elevated levels of neutralizing interleukin-1 receptor antagonist autoantibodies. Their induction is thought to result from a combination of host-related factors, such as human leukocyte antigen class II alleles, and interleukin-1 receptor antagonist intrinsic factors, including hyperphosphorylation. Despite frequent detection of these antibodies using immunoassays and functional cell-based assays, the lack of assay standardization limits their clinical utility. At present, their presence is best regarded as a marker of underlying immune dysregulation rather than a direct pathogenic driver.
Publish Date 2026-04-23 11:05
Citation

Bouayad A. Interleukin-1 receptor antagonist autoantibodies in Still’s disease: Mechanistic insights and laboratory testing. World J Methodol 2026; 16(2): 114269

URL https://www.wjgnet.com/2222-0682/full/v16/i2/114269.htm
DOI https://dx.doi.org/10.5662/wjm.v16.i2.114269
Full Article (PDF) WJM-16-114269-with-cover.pdf